The follow up study of "Phase l / ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type (JACCRO CC-06)".
Phase of Trial: Phase IV
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms JACCRO CC-06 B
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2017 New trial record